The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, moreso than previously reported. Anti-3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies have been linked to the immune-mediated necrotizing myopathy (IMNM). Such antibodies have been often implicted with statin (and other exogenous substances) induced necrotizing myositis.

Post-vaccination disease flares were uncommon among patients with rheumatic and musculoskeletal diseases who were inoculated against COVID-19, researchers found.

A retrospective analysis of the ACR RISE registry shows that multimorbidity is not only common in patients with active rheumatoid arthritis (RA), but also impacts treatment choices and outcomes.

Randomized clinical trials in primary Sjögren's syndrome (pSS) are fraught with fault and inconclusive outcome measures, including the more recently developed EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI).  There's a new composite endpoint outcome for RCTs in pSS, called the Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS).